OvaScience Gets a Sell from Credit Suisse

By Jason Carr

In a report released today, Kennen MacKay from Credit Suisse resumed coverage with a Sell rating on OvaScience (NASDAQ: OVAS). The company’s shares opened today at $1.50.

According to TipRanks.com, MacKay is a 5-star analyst with an average return of 17.1% and a 63.8% success rate. MacKay covers the Healthcare sector, focusing on stocks such as Five Prime Therapeutics, Akebia Therapeutics, and Puma Biotechnology.

OvaScience has an analyst consensus of Hold, with a price target consensus of $15.

Based on OvaScience’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $121K and GAAP net loss of $22.64 million. In comparison, last year the company earned revenue of $146K and had a GAAP net loss of $21.76 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female’s egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA.